Zoetis Q4 Beat, OA Antibodies and Vaccine Gains Q1

Introduction

Zoetis (ZTS) closed out 2025 with a solid quarter and a forward-looking outlook that underscores its commercial momentum across diagnostics, genetic tests, and biodevices. Recent regulatory approvals for long‑acting companion‑animal antibody therapies and conditional veterinary vaccine licenses add tangible product catalysts to the company’s financial guidance. This article summarizes the key facts from Zoetis’s latest release, highlights the items most relevant to investors, and explains why these operational wins matter for ZTS.

Quarterly and Full‑Year Results: The Numbers That Moved ZTS

Q4 2025 performance

On February 12, 2026, Zoetis reported Q4 2025 revenue of approximately $2.4 billion, up about 3% year‑over‑year, with adjusted earnings per share of $1.48. The company achieved modest organic operational growth (roughly 4% on an organic basis) — a signal that demand across veterinary pharmaceuticals and related services remains steady despite macroeconomic headwinds.

Full‑year 2025 and 2026 guidance

Full‑year revenue finished near $9.5 billion, a 2% increase over 2024, with adjusted EPS at $6.41. For 2026 Zoetis provided guidance calling for revenue between $9.825 billion and $10.025 billion, and adjusted EPS in the $7.00–$7.10 range. The company also forecasted 3%–5% organic operational revenue growth for 2026. These figures are concrete data points investors use to re‑price ZTS against peers and the S&P 500.

Product and Regulatory Milestones: Direct Revenue Catalysts

Long‑acting OA antibodies for dogs and cats

Zoetis secured approvals in Canada and the European Union for Lenivia® (canine) and Portela® (feline), long‑acting monoclonal antibodies designed to reduce osteoarthritis pain with infrequent dosing. These agents can extend treatment duration with a single injection lasting up to three months, which is commercially meaningful: longer dosing intervals can improve adherence and raise lifetime value per patient. For ZTS, that translates into a clearer revenue runway in the companion‑animal segment, where therapies already command premium pricing.

Conditional and international vaccine approvals

Alongside companion‑animal advances, Zoetis obtained conditional FDA clearances or international approvals for several livestock and poultry products — notably H5N2 avian influenza vaccines and Dectomax‑CA1 for prevention of New World screwworm in cattle. The company also rolled out regional approvals for products like Synovex Primer and a needle‑free PRRS vaccine in the UK. These approvals bolster recurring revenue opportunities in large‑animal biodevices and herd‑health programs.

Why These Events Matter to ZTS Investors

Tangible pipeline wins vs. speculative leverage

Unlike speculative headlines about future technologies, the recent items are regulatory facts: approvals and guidance tied to defined commercial launches. That distinction matters for investors because realized approvals reduce binary regulatory risk and provide a clearer timetable for revenue recognition. Companion‑animal therapeutics with extended dosing intervals are especially valuable because they can drive both product uptake and price resilience.

Impact on near‑term valuation and cash flow

Zoetis’s combination of steady revenue growth and the 2026 guidance range supports expectations for modest EPS expansion. New product rollouts (OA antibodies, vaccines) can accelerate unit growth in higher‑margin therapeutic areas and strengthen recurring service revenue tied to diagnostics and herd‑level biodevice deployments. For valuation, that shifts ZTS from a pure defensive animal‑health name toward one with identifiable organic growth contributors.

Risks and Execution Factors

Execution will determine how much the approvals move the needle. Critical variables include launch cadence, pricing and reimbursement in different jurisdictions, veterinarian and owner adoption for long‑acting therapies, and supply‑chain readiness for vaccine rollouts. Additionally, competitive responses and any label or safety updates will influence uptake. These are measurable operational metrics investors should track alongside quarterly financials.

Conclusion

Zoetis’s latest quarter and 2026 guidance show steady core performance, while approvals for long‑acting osteoarthritis antibodies and several veterinary vaccines provide concrete, near‑term product catalysts. These developments reduce regulatory uncertainty and create identifiable paths to incremental revenue, supporting a constructive—but execution‑dependent—view on ZTS. Investors should monitor launch metrics, adoption rates in companion and large‑animal markets, and quarterly updates to assess how these approvals translate into sustained top‑line and margin expansion.